Since ACE2 is a functional receptor for SARS-CoV-2, researchers started to carefully consider the safety and potential effects of antihypertension therapy with ACE inhibitors or angiotensin-receptor blockers in patients with COVID-19. This evidence concerns the gene ACE and COVID-19.